Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 20 analyst reports since August 12, 2015 according to SRatingsIntel. FBR Capital maintained the shares of TGTX in report on Monday, December 11 with “Buy” rating. The stock has “Buy” rating by Brean Capital on Thursday, October 6. H.C. Wainwright maintained TG Therapeutics, Inc. (NASDAQ:TGTX) on Tuesday, March 7 with “Buy” rating. The firm earned “Buy” rating on Monday, December 11 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, November 14. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Strong Buy” rating given on Wednesday, September 9 by Raymond James. The firm has “Outperform” rating by FBR Capital given on Tuesday, December 1. The firm has “Buy” rating by SunTrust given on Friday, May 27. On Wednesday, August 12 the stock rating was upgraded by Zacks to “Hold”. The firm has “Buy” rating by FBR Capital given on Thursday, June 15. See TG Therapeutics, Inc. (NASDAQ:TGTX) latest ratings:
09/03/2018 Broker: FBR Capital Rating: Buy New Target: $27.0 Maintain
02/02/2018 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
17/01/2018 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
12/12/2017 Broker: Raymond James Rating: Buy
11/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $33.0 Maintain
11/12/2017 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
01/12/2017 Broker: B. Riley & Co Rating: Buy New Target: $21.5 Maintain
30/11/2017 Broker: FBR Capital Rating: Buy New Target: $21.5
14/11/2017 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $33 Reinitiate
18/10/2017 Broker: SunTrust Rating: Buy
The stock of TopBuild Corp. (NYSE:BLD) hit a new 52-week high and has $86.66 target or 7.00% above today’s $80.99 share price. The 7 months bullish chart indicates low risk for the $2.88 billion company. The 1-year high was reported on Mar, 14 by Barchart.com. If the $86.66 price target is reached, the company will be worth $201.46 million more. The stock increased 1.14% or $0.91 during the last trading session, reaching $80.99. About 74,051 shares traded. TopBuild Corp. (NYSE:BLD) has risen 51.26% since March 14, 2017 and is uptrending. It has outperformed by 34.56% the S&P500.
TopBuild Corp. engages in the installation, distribution, and sale of insulation and other building products to the United States construction industry. The company has market cap of $2.88 billion. The firm operates in two divisions, Installation and Distribution. It has a 18.75 P/E ratio. It offers rain gutters, garage doors, fireplaces, fireproofing and firestopping products, shower enclosures, closet shelves, accessories, and other building products; and residential insulation services.
Analysts await TopBuild Corp. (NYSE:BLD) to report earnings on May, 8. They expect $0.69 EPS, up 50.00% or $0.23 from last year’s $0.46 per share. BLD’s profit will be $24.52 million for 29.34 P/E if the $0.69 EPS becomes a reality. After $0.84 actual EPS reported by TopBuild Corp. for the previous quarter, Wall Street now forecasts -17.86% negative EPS growth.
Among 9 analysts covering TopBuild (NYSE:BLD), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. TopBuild has $90.0 highest and $32 lowest target. $62.44’s average target is -22.90% below currents $80.99 stock price. TopBuild had 18 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of TopBuild Corp. (NYSE:BLD) earned “Neutral” rating by Macquarie Research on Wednesday, November 4. As per Wednesday, February 28, the company rating was maintained by Stephens. KeyBanc Capital Markets maintained the shares of BLD in report on Thursday, October 12 with “Buy” rating. The firm earned “Buy” rating on Thursday, January 11 by KeyBanc Capital Markets. KeyBanc Capital Markets maintained TopBuild Corp. (NYSE:BLD) rating on Tuesday, December 19. KeyBanc Capital Markets has “Buy” rating and $85.0 target. SunTrust maintained it with “Buy” rating and $75.0 target in Wednesday, October 4 report. The firm earned “Neutral” rating on Wednesday, November 8 by Nomura. KeyBanc Capital Markets maintained TopBuild Corp. (NYSE:BLD) rating on Friday, November 10. KeyBanc Capital Markets has “Overweight” rating and $69 target. The firm has “Overweight” rating by KeyBanc Capital Markets given on Thursday, January 5. The rating was maintained by SunTrust with “Buy” on Wednesday, August 12.
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $1.17 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.
Investors sentiment increased to 2 in 2017 Q3. Its up 0.79, from 1.21 in 2017Q2. It improved, as 11 investors sold TG Therapeutics, Inc. shares while 22 reduced holdings. 11 funds opened positions while 29 raised stakes. 35.13 million shares or 3.60% more from 33.91 million shares in 2017Q2 were reported. Retail Bank Of America Corp De holds 9,998 shares. Victory Cap accumulated 3,056 shares. American Intl Group owns 32,535 shares. Ameritas Prtnrs holds 0% or 4,260 shares in its portfolio. Segall Bryant & Hamill Ltd Liability has 53,592 shares. Pub Employees Retirement Association Of Colorado has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Ubs Asset Americas owns 0.01% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 1.09 million shares. Citadel Advsrs Ltd Co has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 111,065 shares. Eam Investors has 0.49% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). Great West Life Assurance Commerce Can invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). 400,000 were reported by Artal Gp Sa. 13,300 are owned by Bb&T Lc. Bessemer Inc accumulated 1,403 shares or 0% of the stock. Hollencrest Secs Lc has invested 0.02% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). 243,485 were reported by Schwab Charles Mgmt Inc.
Since December 29, 2017, it had 0 insider buys, and 1 sale for $272,051 activity. Power Sean A also sold $272,051 worth of TG Therapeutics, Inc. (NASDAQ:TGTX) on Friday, December 29.